Laura Vidal, MD

Laura Vidal, MD, is a certified medical oncologist with extensively experience in oncology drug. She holds two fellowships in Clinical Drug Development from the Royal Marsden hospital, London and the Princess Margaret Hospital, Toronto. She spent 15 years in clinical and academic positions specializing in the field on oncology and drug development. Throughout her career, Dr. Vidal has authored or co-authored dozens of peer-reviewed journal articles and received numerous health and research awards. Her research interests are focused on early phase development of targeted agents, molecular and imaging biomarkers and anticancer immunotherapy. She holds a thesis title from the London University in oncolytic viruses from her pre-clinical and clinical work in reovirus (Reolysin®). 

She joined our company in December 2020. Dr. Laura Vidal is the Medical Head of the Oncology group in EU. She contributes to the development of Fortrea policies involving medical, safety and therapeutics; serves as point of contact for key clients on business and studies oversight; manages relationships with investigators/sites for clinical trials, and mentors clinical research physicians and medical directors across the company.

Publications

• The Evolving Landscape in Multiple Myeloma: From Risk Stratification to T Cell-Directed Advanced Therapies
• Bladder Cancer, Loss of Y Chromosome, and New Opportunities for Immunotherapy
• Equitable inclusion of diverse populations in oncology clinical trials: deterrents and drivers
• Cancer Trials Ecosystem in India—Ready for Prime Time?
• Biomarkers in head and neck squamous cell carcinoma: unraveling the path to precision immunotherapy
• Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in advanced non-small cell lung cancer
• Mechanisms of immune modulation in the tumor microenvironment and implications for targeted therapy
• Intracellular DNA sensing by neutrophils and amplification of the innate immune response
• Recent Advances in Gynecological Malignancies: Focus on ASCO 2023
• Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer
• Window of opportunity trials with immune checkpoint inhibitors in triple-negative breast cancer